A Phase 1 interventional study of Etavopivat and Digoxin in Healthy Volunteers Sickle Cell Disease, Thalassemia, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Thalassemia with a site in United States — 9 open to participants now, 20 under way, 8 of them phase 3. Thalassemia · United States.
Among the 104 studies in Thalassemia with a site in United States, this one is the 26th largest by enrollment of the 81 interventional ones that give a count, is one of 4 that started in 2025, is one of 14 in phase 1, and was the 100th registered.
250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.
Browse Thalassemia studies →9 of the 104 studies in Thalassemia with a site in United States are open now. Recruiting first, the newest first:
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
Novo Nordisk A/S · Sites in United States, Canada, Egypt and 14 more countries
Ages 2+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 2–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 44 · Phase 3 13 · Phase 4 2
First in 1985; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is above the median of 33 across 170 interventional studies indexed under Thalassemia.
Median enrollment 24 across the 81 interventional studies, 125 across the 20 observational. Of the 78 that completed or were terminated, 33 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 104 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Novo Nordisk A/S has 6 studies filed under Thalassemia — fewer than ten, so there is no comparison to draw.
7 of the studies in Thalassemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT07064941University of California, San FranciscoEffect of Exercise on Body Composition and Bone Health in Patients With Thalassemia | 2026-12-30 |
| NCT03249831City of Hope Medical CenterA Blood Stem Cell Transplant for Sickle Cell Disease | 2027-01-25 |
| NCT05736419Memorial Sloan Kettering Cancer CenterA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) | 2027-02-09 |
Add all 7 to your calendar (.ics) → With an account.
Among the 104 studies in Thalassemia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs and they are: digoxin, pitavastatin, metformin, midazolam, and rosuvastatin. During a period of the study, participants will take 2 tablets of etavopivat daily for 10 consecutive days. The study will last for about 34 to 64 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of oral digoxin, pitavastatin and metformin.
Drug: Digoxin · Drug: Pitavastatin · Drug: Metformin
Participants will receive a single dose of oral midazolam and rosuvastatin.
Drug: Midazolam · Drug: Rosuvastatin
Participants will receive a daily dose of oral etavopivat and single dose of oral midazolam.
Drug: Etavopivat · Drug: Midazolam
Participants will receive a daily dose of oral etavopivat, single dose of oral midazolam and rosuvastatin.
Drug: Etavopivat · Drug: Midazolam · Drug: Rosuvastatin
Participants will receive a daily dose of oral etavopivat, single dose of oral digoxin, pitavastatin and metformin.
Drug: Etavopivat · Drug: Digoxin · Drug: Pitavastatin · Drug: Metformin
Participants will receive a daily dose of etavopivat orally.
Participants will receive a single dose of digoxin orally.
Participants will receive a single dose of pitavastatin orally.
Participants will receive a single dose of metformin orally.
Participants will receive a single dose of midazolam orally.
Participants will receive a single dose of rosuvastatin orally.
Cmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady state
Measured as picograms per milliliter (pg/mL).
Time frame: Day 1 and day 3 after digoxin administration
AUC0-inf, digoxin, SD: Area under the digoxin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state
Measured as hours\*picograms per milliliter (h\*pg/mL).
Time frame: Day 1 and day 3 after digoxin administration
Cmax, rosuvastatin, SD: Maximum observed rosuvastatin plasma concentration with and without etavopivat at steady state
Measured as pg/mL.
Time frame: Day 1 after rosuvastatin administration
AUC0-inf, rosuvastatin, SD: Area under the rosuvastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state
Measured as h\*pg/mL.
Time frame: Day 1 after rosuvastatin administration
Cmax, midazolam, SD: Maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as pg/mL.
Time frame: Day 1 after midazolam administration
AUC0-inf, midazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours and extrapolated to infinity without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as h\*pg/mL.
Time frame: Day 1 after midazolam administration
Cmax, pitavastatin, SD: Maximum observed pitavastatin plasma concentration with and without etavopivat at steady state
Measured as nanograms per milliliter (ng/mL).
Time frame: Day 1 and day 3 after pitavastatin administration
AUC0-inf, pitavastatin, SD: Area under the pitavastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state
Measured as hours\*nanograms per milliliter(h\*ng/mL).
Time frame: Day 1 and day 3 after pitavastatin administration
Cmax, metformin, SD: Maximum observed metformin plasma concentration with and without etavopivat at steady state
Measured as ng/mL.
Time frame: Day 1 and day 3 after metformin administration
AUC0-inf, metformin, SD: Area under the metformin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state
Measured as h\*ng/mL.
Time frame: Day 1 and day 3 after metformin administration
AUC0-last, digoxin, SD: Area under the digoxin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state
Measured as h\*pg/mL.
Time frame: Day 1 and day 3 after digoxin administration
t1/2, digoxin, SD: Terminal half-life for digoxin with and without etavopivat at steady state
Measured as hours.
Time frame: Day 1 and day 3 after digoxin administration
tmax, digoxin, SD: Time to maximum observed digoxin plasma concentration with and without etavopivat at steady state
Measured as hours.
Time frame: Day 1 and day 3 after digoxin administration
CL/Fdigoxin, SD: Apparent plasma clearance of digoxin with and without etavopivat at steady state
Measured as liters per hour (L/h).
Time frame: Day 1 and day 3 after digoxin administration
Vz/Fdigoxin, SD: Apparent volume of distribution of digoxin with and without etavopivat at steady state based on plasma concentration values
Measured as liters (L).
Time frame: Day 1 and day 3 after digoxin administration
AUC0-last, rosuvastatin, SD: Area under the rosuvastatin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state
Measured as h\*pg/mL.
Time frame: Day 1 after rosuvastatin administration
t1/2, rosuvastatin, SD: Terminal half-life for rosuvastatin with and without etavopivat at steady state
Measured as hours.
Time frame: Day 1 after rosuvastatin administration
tmax, rosuvastatin, SD: Time to maximum observed rosuvastatin plasma concentration with and without etavopivat at steady state
Measured as hours.
Time frame: Day 1 after rosuvastatin administration
CL/Frosuvastatin, SD: Apparent plasma clearance of rosuvastatin with and without etavopivat at steady state
Measured as L/h.
Time frame: Day 1 after rosuvastatin administration
Vz/Frosuvastatin, SD: Apparent volume of distribution of rosuvastatin with and without etavopivat at steady state based on plasma concentration values
Measured as L.
Time frame: Day 1 after rosuvastatin administration
AUC0-last, midazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours to the last quantifiable concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as h\*pg/mL.
Time frame: Day 1 after midazolam administration
t1/2, midazolam, SD: Terminal half-life for midazolam without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as hours.
Time frame: Day 1 after midazolam administration
tmax, midazolam, SD: Time to maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as hours.
Time frame: Day 1 after midazolam administration
CL/Fmidazolam, SD: Apparent plasma clearance of midazolam without etavopivat, with a single dose of etavopivat and with etavopivat at steady state
Measured as L/h.
Time frame: Day 1 after midazolam administration
Vz/Fmidazolam, SD: Apparent volume of distribution of midazolam without etavopivat, with a single dose of etavopivat and with etavopivat at steady state
Measured as L.
Time frame: Day 1 after midazolam administration
AUC0-inf, 1-hydroxymidazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours and extrapolated to infinity without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as h\*pg/mL.
Time frame: Day 1 after midazolam administration
Cmax, 1-hydroxymidazolam, SD: Maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as pg/mL.
Time frame: Day 1 after midazolam administration
AUC0-last, 1-hydroxymidazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours to the last quantifiable concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as h\*pg/mL.
Time frame: Day 1 after midazolam administration
t1/2, 1-hydroxymidazolam: Terminal half-life for 1-hydroxymidazolam without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as hours.
Time frame: Day 1 after midazolam administration
tmax, 1-hydroxymidazolam: Time to maximum observed 1-hydroxymidazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as hours.
Time frame: Day 1 after midazolam administration
CL/F1-hydroxymidazolam: Apparent plasma clearance of 1-hydroxymidazolam without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as L/h.
Time frame: Day 1 after midazolam administration
Vz/F1-hydroxymidazolam: Apparent volume of distribution of 1-hydroxymidazolam based on plasma concentration values without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state
Measured as L.
Time frame: Day 1 after midazolam administration
AUC0-last, pitavastatin, SD: Area under the pitavastatin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state
Measured as h\*ng/mL.
Time frame: Day 1 and day 3 after pitavastatin administration
t1/2, pitavastatin, SD: Terminal half-life for pitavastatin with and without etavopivat at steady state
Measured as hours.
Time frame: Day 1 and day 3 after pitavastatin administration
tmax, pitavastatin, SD: Time to maximum observed pitavastatin plasma concentration with and without etavopivat at steady state
Measured as hours.
Time frame: Day 1 and day 3 after pitavastatin administration
CL/Fpitavastatin, SD: Apparent plasma clearance of pitavastatin with and without etavopivat at steady state
Measured as L/h.
Time frame: Day 1 and day 3 after pitavastatin administration
Vz/Fpitavastatin, SD: Apparent volume of distribution of pitavastatin with and without etavopivat at steady state based on plasma concentration values
Measured as L.
Time frame: Day 1 and day 3 after pitavastatin administration
AUC0-last, metformin, SD: Area under the metformin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state
Measured as h\*ng/mL.
Time frame: Day 1 and day 3 after metformin administration
t1/2, metformin, SD: Terminal half-life for metformin with and without etavopivat at steady state
Measured as hours.
Time frame: Day 1 and day 3 after metformin administration
tmax, metformin, SD: Time to maximum observed metformin plasma concentration with and without etavopivat at steady state
Measured as hours.
Time frame: Day 1 and day 3 after metformin administration
CL/Fmetformin, SD: Apparent plasma clearance of metformin with and without etavopivat at steady state
Measured as L/h.
Time frame: Day 1 and day 3 after metformin administration
Vz/Fmetformin, SD: Apparent volume of distribution of metformin with and without etavopivat at steady state based on plasma concentration values
Measured as L.
Time frame: Day 1 and day 3 after metformin administration
Aelast, metformin, SD%: Percentage of the metformin excreted into urine from the time of dosing to the collection time of the last measurable concentration with and without etavopivat at steady state
Measured as percentage (%) of the metformin excreted into urine.
Time frame: Day 1 and day 3 after metformin administration
CLR, metformin, SD: Renal clearance of metformin
Measured as L/h.
Time frame: Day 1 and day 3 after metformin administration
AUC0-tau, etavopivat: Area under the etavopivat plasma concentration-time curve during one dosing interval at single dose and at steady state
Measured as h\*ng/mL.
Time frame: Day 1 and day 3 after etavopivat administration
AUC0-last etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours to the last quantifiable concentration at single dose and at steady state
Measured as h\*ng/mL.
Time frame: Day 1 and day 3 after etavopivat administration
Cmax, etavopivat: Maximum observed etavopivat plasma concentration at single dose and at steady state
Measured as ng/mL.
Time frame: Day 1 and day 3 after etavopivat administration
t1/2, etavopivat: Terminal half-life for etavopivat at single dose and at steady state
Measured as hours.
Time frame: Day 1 and day 3 after etavopivat administration
tmax, etavopivat: Time to maximum observed etavopivat plasma concentration at single dose and at steady state
Measured as hours.
Time frame: Day 1 and day 3 after etavopivat administration
V/Fetavopivat: Apparent volume of distribution of etavopivat based on plasma concentration values at single dose and at steady state
Measured as L.
Time frame: Day 1 and day 3 after etavopivat administration
CL/Fetavopivat: Apparent plasma clearance of etavopivat at single dose and at steady state
Measured as L/h.
Time frame: Day 1 and day 3 after etavopivat administration
C, etavopivat: Observed etavopivat plasma concentration after single and multiple doses
Measured as ng/mL.
Time frame: From day 1 to day 4 after administration of etavopivat
Number of adverse events (AEs)
Measured as count of events.
Time frame: From first dose (day 1) until end of study (day 32)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in May 2025, 3 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Etavopivat · Digoxin · Pitavastatin · Metformin · Midazolam · Rosuvastatin